Please login to the form below

Not currently logged in

Gyroscope Therapeutics appoints CEO

Dr Soraya Bekkali joins from biotech firm Lysogene

Ophthalmology group Gyroscope Therapeutics has appointed Dr Soraya Bekkali as its chief executive officer and director of its board.

She has over 20 years’ industry experience and moves to the London-based biotech firm from Lysogene where she served as the French biotechnology company's senior vice president and chief medical officer.

She said: “I am excited to be joining Gyroscope at the company’s founding stage to advance new genetically-defined therapies for the treatment of debilitating eye diseases such as age-related macular degeneration.

“Gyroscope has a unique translational approach to tackling complex diseases such as dry AMD for which there are no therapies today.”

Dr Bekkali’s previous leadership positions include global head of the ophthalmology business unit at Sanofi, where she led its ophthalmology strategy towards ocular gene therapy and set up a multidisciplinary team.

Chris Hollowood, chairman of the board and chief investment office at Syncona, said: “We are extremely pleased to appoint Soraya and look forward to her leadership and extensive gene therapy and ophthalmology clinical experience driving the company forward.”

10th October 2017

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...